Pomalyst (Pomalidomide)
pomalidomide — immunomodulatory imide drug (IMiD), thalidomide analogue
Indications for Pomalidomide
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Multiple myeloma — relapsed/refractory | Adults who received ≥2 prior therapies including lenalidomide and a proteasome inhibitor, with disease progression on or within 60 days of last therapy | Combination with dexamethasone | FDA Approved |
| AIDS-related Kaposi sarcoma | Adults; after failure of HAART | Monotherapy (continue HAART) | Accelerated Approval |
| Kaposi sarcoma — HIV-negative | Adults | Monotherapy | Accelerated Approval |
Pomalidomide is a third-generation immunomodulatory drug (IMiD) that was first approved by the FDA in 2013 for relapsed/refractory multiple myeloma. It is structurally related to both thalidomide and lenalidomide and retains activity against myeloma cells that have become resistant to lenalidomide. The drug received an expanded indication in 2020 for Kaposi sarcoma under accelerated approval based on overall response rate. Like all IMiDs, pomalidomide is available only through a mandatory REMS program (PS-Pomalidomide REMS) due to its teratogenic potential as a thalidomide analogue.
Myelofibrosis — used in combination with ruxolitinib or as second-line monotherapy. Evidence quality: Moderate.
Systemic AL amyloidosis — pomalidomide-based regimens for relapsed/refractory disease. Evidence quality: Moderate.
Waldenström macroglobulinaemia — in combination with dexamethasone and rituximab. Evidence quality: Low-moderate.
Dosing for Pomalidomide
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Relapsed/refractory MM — with low-dose dexamethasone | 4 mg PO daily, Days 1–21 of 28-day cycles | 4 mg PO daily, Days 1–21 | 4 mg/day | With dexamethasone (see PI Section 14.1 for dex dosing); continue until progression Reduce by 1 mg per step for Grade 3/4 toxicity (minimum tolerated: 1 mg; d/c if unable to tolerate 1 mg) |
| Kaposi sarcoma (AIDS-related or HIV-negative) | 5 mg PO daily, Days 1–21 of 28-day cycles | 5 mg PO daily, Days 1–21 | 5 mg/day | Continue HAART in HIV-positive patients; continue until progression or unacceptable toxicity Different dose reduction thresholds vs MM (see PI Table 2) |
Dose Adjustments for Special Populations
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Strong CYP1A2 inhibitor co-administration (e.g. fluvoxamine, ciprofloxacin) | 2 mg PO daily | 2 mg PO daily | 2 mg/day | Avoid if possible; fluvoxamine increases AUC by 125% and Cmax by 24% |
| MM — severe renal impairment (dialysis) | 3 mg PO daily | 3 mg PO daily | 3 mg/day | Administer after dialysis on dialysis days AUC increased by 38% in dialysis patients; SAE rate 64% higher |
| KS — severe renal impairment (dialysis) | 4 mg PO daily | 4 mg PO daily | 4 mg/day | Administer after dialysis on dialysis days |
| MM — mild or moderate hepatic impairment (Child-Pugh A or B) | 3 mg PO daily | 3 mg PO daily | 3 mg/day | AUC increased by ~51–58% in mild/moderate HI |
| MM — severe hepatic impairment (Child-Pugh C) | 2 mg PO daily | 2 mg PO daily | 2 mg/day | AUC increased by ~72% in severe HI |
| KS — any hepatic impairment (Child-Pugh A, B, or C) | 3 mg PO daily | 3 mg PO daily | 3 mg/day | Same dose regardless of hepatic impairment severity in KS |
For MM: withhold pomalidomide if ANC <500/mcL or platelets <25,000/mcL; resume at 1 mg less than the previous dose when ANC ≥500/mcL or platelets ≥50,000/mcL. For KS: thresholds differ — ANC <500/mcL requires hold, but ANC 500–1000/mcL allows continued treatment at the same dose during a cycle. Platelets <25,000/mcL in KS requires permanent discontinuation, not dose reduction. These indication-specific differences are clinically critical (FDA PI Tables 1 and 2).
Pharmacology of Pomalidomide
Mechanism of Action
Pomalidomide is a third-generation cereblon-binding immunomodulatory agent that exerts its anticancer effects through multiple complementary mechanisms. Like lenalidomide, it binds to cereblon (CRBN), a component of the CRL4CRBN E3 ubiquitin ligase complex, redirecting the ligase to ubiquitinate and degrade the lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). This degradation directly induces apoptosis in myeloma cells and activates T-cell and NK-cell immunity. Pomalidomide demonstrates activity in lenalidomide-resistant myeloma cells and synergises with dexamethasone to overcome drug resistance. Additionally, pomalidomide possesses potent anti-angiogenic properties through inhibition of VEGF and bFGF, modulates the tumour microenvironment by altering cytokine profiles, and has direct anti-proliferative effects on KS-associated herpesvirus-infected cells, providing the rationale for its efficacy in Kaposi sarcoma.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Well absorbed orally; Tmax ~2–3 h; food does not significantly affect bioavailability; may be taken with or without food | Swallow capsules whole; do not break, chew, or open |
| Distribution | Protein binding 12–44%; distributes into semen; peripheral Vd ~8-fold higher in MM patients vs healthy subjects | Low-moderate protein binding supports dialytic removal; semen distribution necessitates male condom use |
| Metabolism | Extensively metabolised: CYP1A2 (~54% contribution) and CYP3A4 (~30%), with minor CYP2C19 (11%) and CYP2D6 (4%); primary pathway: hydroxylation (43% of dose) followed by glucuronidation; hydrolysis (25%); only ~10% excreted unchanged | Strong CYP1A2 inhibitors double exposure (dose reduce to 2 mg); smoking (CYP1A2 induction) reduces AUC by ~32% — advise patients of reduced efficacy with smoking |
| Elimination | t½ ~7.5 h in MM patients (mass balance: 8.9–11.2 h); 73% of radioactive dose in urine, 15% in faeces; total recovery ~88% within 10 days | Hepatic metabolism is the primary clearance pathway (unlike lenalidomide which is renally eliminated unchanged); dose adjustment needed for hepatic impairment |
Unlike lenalidomide (which is renally eliminated largely unchanged with a 3–4 hour half-life), pomalidomide undergoes extensive hepatic metabolism via CYP1A2 and CYP3A4, with only 10% excreted unchanged in urine. This means hepatic impairment significantly increases pomalidomide exposure (requiring dose reduction), while renal impairment has a more modest effect. Conversely, CYP1A2 inhibitors and inducers (including smoking) meaningfully alter pomalidomide levels — an interaction that does not occur with lenalidomide.
Side Effects of Pomalidomide
| Adverse Effect | Incidence (Trials 1–2) | Clinical Note |
|---|---|---|
| Fatigue / asthenia | 47–63% | Most common non-haematologic adverse reaction; dose-related |
| Neutropenia | 49–51% (Grade 3/4: 41–48%) | Dose-limiting toxicity; Grade 3/4 in approximately half of all patients |
| Anaemia | 38–42% (Grade 3/4: 21–23%) | May require transfusion support |
| Constipation | 36–37% | May reflect concurrent dexamethasone or opioid use |
| Diarrhoea | 35–36% | Manage symptomatically; monitor hydration |
| Dyspnoea | 25–45% | Assess for PE, pneumonia, or cardiac causes before attributing to drug |
| Back pain | 32–35% (Grade 3/4: 10–14%) | May indicate disease progression; rule out skeletal events |
| Upper respiratory tract infection | 29–37% | Usually mild; differentiate from pneumonia |
| Pyrexia | 27–32% | Rule out febrile neutropenia (rate 8–9%) and infection |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Pneumonia | 19–34% (Grade 3/4: 16–29%) | Very high serious rate; majority Grade 3/4; assess for opportunistic pathogens including PJP; patients ≥65 years at highest risk |
| Thrombocytopenia | 23–30% (Grade 3/4: 19–22%) | Monitor for bleeding; dose interruption per protocol |
| Nausea | 15–36% | Usually mild; anti-emetics as needed |
| Peripheral neuropathy | 12–21% (Grade 3: 2%) | Consider baseline assessment; differentiate from prior bortezomib-related neuropathy |
| Dizziness | 14–22% | Grade 3/4 in ~1%; advise caution with driving/machinery |
| Rash | 16–21% | Discontinue for SJS/TEN/DRESS or Grade 4 rash |
| Muscle spasms | 15–21% | Often nocturnal; magnesium supplementation may help |
| Peripheral oedema | 17–25% | Differentiate from cardiac or renal causes |
| Confusional state | 12–15% (Grade 3/4: 3–6%) | May reflect concurrent dexamethasone; assess for metabolic causes |
| Bone pain | 7–18% (Grade 3/4: up to 7%) | Assess for pathological fracture or disease progression |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Venous thromboembolism (DVT, PE) | VTE 4.7% vs 1.3% (Trial 2) | Variable; mandated thromboprophylaxis in trials | Thromboprophylaxis recommended; choice based on individual risk assessment |
| Arterial thromboembolism (MI, stroke) | ATE 3.0% vs 1.3% (Trial 2) | Variable | Modify risk factors; immediate specialist referral |
| Febrile neutropenia | 8–9% | During treatment cycles | Withhold pomalidomide; G-CSF support; antimicrobial therapy |
| Severe pneumonia (Grade 3/4) | 16–29% | Any time during treatment | Hospitalisation; broad-spectrum antibiotics; assess for PJP and atypical pathogens |
| Hepatotoxicity (including fatal hepatic failure) | Fatal cases reported (post-marketing) | Variable | Monitor LFTs monthly; stop pomalidomide for elevated liver enzymes; may restart at lower dose |
| SJS / TEN / DRESS | Rare; can be fatal | Variable | Permanently discontinue; do not rechallenge |
| Embryo-fetal toxicity | Teratogenic in rats and rabbits at all doses | Any exposure during pregnancy | Contraindicated in pregnancy; REMS program mandatory; 2 forms of contraception for 4 weeks before, during, and 4 weeks after treatment |
| Tumour lysis syndrome | Reported (post-marketing) | Early cycles; high tumour burden | Monitor electrolytes; hydration and allopurinol in high-risk patients |
Pomalidomide-treated patients experience a notably high rate of pneumonia (19–34% across trials), with a substantial proportion being Grade 3/4 (16–29%) and classified as serious adverse reactions. In Trial 2 (the pivotal Phase 3 study), Grade 3/4 pneumonia occurred in 16% of the pomalidomide arm versus 10% with high-dose dexamethasone alone. This rate exceeds that seen with lenalidomide and warrants vigilant clinical monitoring. Consider antimicrobial prophylaxis (including PJP prophylaxis) in high-risk patients. Patients older than 65 years are at particular risk (FDA PI Section 8.5).
Drug Interactions with Pomalidomide
Pomalidomide is primarily metabolised by CYP1A2 and CYP3A4 but is not an inhibitor or inducer of CYP450 enzymes. The major clinically significant interaction involves strong CYP1A2 inhibitors, which can approximately double pomalidomide exposure. Smoking induces CYP1A2 and may reduce pomalidomide efficacy.
Monitoring for Pomalidomide
- CBC with DifferentialMM: weekly ×8 wk, then monthly; KS: every 2 wk ×12 wk, then monthly
RoutineNeutropenia is the dose-limiting toxicity. Grade 3/4 neutropenia in 41–50% of patients. Follow indication-specific thresholds for dose interruption (MM: ANC <500; KS: ANC <500 for hold, 500–1000 allows continuation). - Pregnancy Testing2 negative tests before starting (10–14 days apart, second within 24 h); weekly ×4 wk, then q4wk (regular) or q2wk (irregular)
RoutineMandatory REMS requirement. Must be documented before each prescription. - Liver Function TestsMonthly
RoutineFatal hepatic failure reported. Stop pomalidomide for elevated liver enzymes; may restart at lower dose after normalisation. - Signs of VTE / ATEEach cycle
Trigger-basedEnsure thromboprophylaxis is prescribed. VTE 4.7% and ATE 3.0% in Trial 2 despite mandated thromboprophylaxis. - Skin ExaminationEach cycle & as symptoms arise
Trigger-basedSJS, TEN, and DRESS reported. Permanently discontinue for severe cutaneous reactions. Rash common (16–71% depending on indication). - Smoking StatusAt baseline and periodically
RoutineSmoking reduces pomalidomide AUC by ~32% through CYP1A2 induction. Counsel patients that smoking may reduce drug efficacy. - Renal & Hepatic FunctionBaseline and periodically
RoutineDose adjustments required for severe renal impairment (dialysis) and any hepatic impairment. AUC increased 38% (dialysis) and 51–72% (hepatic impairment).
Contraindications & Cautions for Pomalidomide
Absolute Contraindications
- Pregnancy — Pomalidomide is a thalidomide analogue; teratogenic in both rats and rabbits. Thalidomide causes mortality at or shortly after birth in about 40% of exposed infants. Contraindicated in females who are pregnant (PI Section 4.1).
- Severe hypersensitivity to pomalidomide — Including angioedema and anaphylaxis (PI Section 4.2).
Relative Contraindications (Specialist Input Recommended)
- Concurrent use with PD-1/PD-L1 inhibitors + dexamethasone in MM — increased mortality observed in clinical trials; not recommended outside controlled studies (PI Section 5.4).
- Severe hepatic impairment without dose adjustment — AUC increased ~72%; mandatory dose reduction to 2 mg (MM) or 3 mg (KS).
Use with Caution
- Elderly patients (≥65 years) — 44% of clinical trial patients were >65; increased pneumonia risk observed in this population.
- Patients with high tumour burden — Risk of tumour lysis syndrome.
- Smokers — CYP1A2 induction reduces pomalidomide AUC by ~32%; may reduce efficacy.
- Patients on strong CYP1A2 inhibitors — Reduce dose to 2 mg if co-administration is unavoidable.
- Patients with procoagulant disorders or prior VTE/ATE history — Thromboprophylaxis mandatory.
Pomalidomide is a thalidomide analogue. Thalidomide causes severe, life-threatening birth defects and embryo-fetal death. Obtain 2 negative pregnancy tests before starting treatment. Two forms of contraception required during and for 4 weeks after stopping. Available only through PS-Pomalidomide REMS.
DVT, PE, myocardial infarction, and stroke occur in patients with MM treated with pomalidomide. In Trial 2, thromboembolism occurred in 8.0% of the pomalidomide + low-dose dexamethasone arm versus 3.3% with high-dose dexamethasone, despite mandated thromboprophylaxis. Thromboprophylaxis is recommended for all patients.
Patient Counselling for Pomalidomide
Purpose of Therapy
Pomalidomide is a capsule taken by mouth that works by boosting the immune system against cancer cells, directly killing myeloma cells, and cutting off the blood supply tumours need to grow. It is used when myeloma has returned after other treatments including lenalidomide and bortezomib, and is also used to treat Kaposi sarcoma.
How to Take
Take capsules whole at approximately the same time each day, with or without food. Do not break, chew, or open capsules. Treatment is given on a 28-day cycle: 21 days on, 7 days off. Do not donate blood during treatment or for 4 weeks after stopping.
Sources
- Pomalyst (pomalidomide) capsules. Full Prescribing Information. Bristol-Myers Squibb (Celgene). Revised February 2025. FDA LabelPrimary source for all dosing, boxed warnings, adverse reactions, REMS requirements, and dose adjustments in this monograph.
- FDA grants accelerated approval to pomalidomide for Kaposi sarcoma. FDA. May 14, 2020. FDA ApprovalRegulatory announcement for the KS indication based on Trial 12-C-0047 ORR data.
- San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003). Lancet Oncol. 2013;14(11):1055-1066. doi:10.1016/S1470-2045(13)70380-2Phase 3 MM-003 (Trial 2) establishing POM + low-dose dex as standard for relapsed/refractory MM, showing PFS and OS benefit.
- Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma (MM-002). Br J Haematol. 2014;164(2):229-236. doi:10.1111/bjh.12645Phase 2 MM-002 (Trial 1) that supported the initial accelerated approval of pomalidomide in 2013.
- Polizzotto MN, Uldrick TS, Wyvill KM, et al. Pomalidomide for symptomatic Kaposi’s sarcoma in people with and without HIV infection: a phase I/II study. J Clin Oncol. 2016;34(34):4125-4131. doi:10.1200/JCO.2016.69.3812Phase I/II NCI trial (12-C-0047) in Kaposi sarcoma demonstrating ORR supporting accelerated approval.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 5.2024. NCCNCurrent NCCN guidelines incorporating pomalidomide + dexamethasone as a preferred option in relapsed/refractory MM.
- Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326-2335. doi:10.1038/leu.2012.119Identification of cereblon as the direct molecular target of both lenalidomide and pomalidomide, establishing the mechanistic basis for IMiD activity.
- Hoffmann M, Kasserra C, Reyes J, et al. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2013;71(2):489-501. doi:10.1007/s00280-012-2040-6Mass balance study establishing pomalidomide metabolic pathways: CYP-mediated hydroxylation (43%), hydrolysis (25%), and unchanged excretion (10%).
- Li Y, Wang X, O’Mara E, et al. Population pharmacokinetics of pomalidomide. J Clin Pharmacol. 2015;55(5):563-572. doi:10.1002/jcph.455Population PK model establishing half-life of ~7.5 h, CL/F of 6.5–10.8 L/h, and increased peripheral distribution in MM patients.
- Li Y, Xu Y, Liu L, et al. In vivo assessment of the effect of CYP1A2 inhibition and induction on pomalidomide pharmacokinetics in healthy subjects. J Clin Pharmacol. 2018;58(12):1528-1538. doi:10.1002/jcph.1145DDI studies quantifying the CYP1A2 inhibitor effect (+125% AUC with fluvoxamine) and CYP1A2 inducer effect (–32% AUC with smoking).
- Li Y, Wang X, O’Mara E, et al. An open-label, phase 1 study to assess the effects of hepatic impairment on pomalidomide pharmacokinetics. Clin Pharmacol Drug Dev. 2019;8(1):93-101. doi:10.1002/cpdd.470Hepatic impairment study showing AUC increases of 51% (mild), 58% (moderate), and 72% (severe), supporting dose reduction recommendations.